Hillevax Inc (HLVX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hillevax Inc (HLVX) has a cash flow conversion efficiency ratio of -0.005x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-789.00K) by net assets ($147.82 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See HLVX equity financing ratio to measure how much of total assets are equity-financed.
Hillevax Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Hillevax Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Hillevax Inc (HLVX) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Hillevax Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hillevax Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sagittarius Life Science
TWO:3205
|
-0.020x |
|
Voss Veksel og Landmandsbank ASA
OL:VVL
|
0.227x |
|
Fleury Michon
PA:ALFLE
|
0.178x |
|
I-Berhad
KLSE:4251
|
0.032x |
|
Bixolon Co. Ltd
KQ:093190
|
0.047x |
|
Topower Co Ltd
TWO:3226
|
0.017x |
|
Bailador Technology Investments Ltd
AU:BTI
|
-0.039x |
|
Horizon Minerals Ltd
AU:HRZ
|
-0.107x |
Annual Cash Flow Conversion Efficiency for Hillevax Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Hillevax Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see Hillevax Inc (HLVX) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $154.49 Million | $-108.79 Million | -0.704x | -115.46% |
| 2023-12-31 | $265.52 Million | $-86.78 Million | -0.327x | -40.90% |
| 2022-12-31 | $267.23 Million | $-61.99 Million | -0.232x | -420.39% |
| 2021-12-31 | $-100.76 Million | $-7.29 Million | 0.072x | -84.22% |
| 2020-12-31 | $-2.77 Million | $-1.27 Million | 0.459x | -35.06% |
| 2019-12-31 | $-671.00K | $-474.00K | 0.706x | -- |
About Hillevax Inc
HilleVax, Inc., a clinical-stage biopharmaceutical company, develops and commercializes vaccines in the United States. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. It has a license agreement with Takeda Vaccines, Inc. to develop and commercialize HIL-214 pharmaceutical prod… Read more